Especially for therapy-refractory B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma, CD19-directed CAR T cell therapy revealed impressive response rates in clinical trials [5,6,7,8]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.